MA34078B1 - Derives d'arylethynyle - Google Patents

Derives d'arylethynyle

Info

Publication number
MA34078B1
MA34078B1 MA35234A MA35234A MA34078B1 MA 34078 B1 MA34078 B1 MA 34078B1 MA 35234 A MA35234 A MA 35234A MA 35234 A MA35234 A MA 35234A MA 34078 B1 MA34078 B1 MA 34078B1
Authority
MA
Morocco
Prior art keywords
derivatives
areletinyl
formula
mglur5
metabotropic
Prior art date
Application number
MA35234A
Other languages
Arabic (ar)
English (en)
Inventor
Luke Green
Wolfgang Guba
Georg Jaeschke
Synese Jolidon
Lothar Lindemann
Antonio Ricci
Daniel Rueher
Heinz Stadler
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34078B1 publication Critical patent/MA34078B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des dérivés d'éthynyle de formule i en tant que modulateurs allostériques des récepteurs métabotropiques de glutamate de sous-type 5 (mglur5). Les variables dans la formule i sont définies dans la description.
MA35234A 2010-04-13 2011-04-11 Derives d'arylethynyle MA34078B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10159754 2010-04-13
PCT/EP2011/055585 WO2011128279A1 (fr) 2010-04-13 2011-04-11 Dérivés d'aryléthynyle

Publications (1)

Publication Number Publication Date
MA34078B1 true MA34078B1 (fr) 2013-03-05

Family

ID=44140916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35234A MA34078B1 (fr) 2010-04-13 2011-04-11 Derives d'arylethynyle

Country Status (33)

Country Link
US (4) US8420661B2 (fr)
EP (1) EP2558457B1 (fr)
JP (1) JP5559418B2 (fr)
KR (1) KR101431367B1 (fr)
CN (1) CN102947289B (fr)
AR (1) AR080878A1 (fr)
AU (1) AU2011240131B2 (fr)
BR (1) BR112012026004A2 (fr)
CA (1) CA2786216C (fr)
CL (1) CL2012002771A1 (fr)
CR (1) CR20120480A (fr)
CY (1) CY1117441T1 (fr)
DK (1) DK2558457T3 (fr)
EC (1) ECSP12012212A (fr)
ES (1) ES2565761T3 (fr)
HR (1) HRP20160617T1 (fr)
HU (1) HUE027105T2 (fr)
IL (1) IL220982A (fr)
MA (1) MA34078B1 (fr)
MX (1) MX2012011841A (fr)
MY (1) MY160490A (fr)
NZ (1) NZ601024A (fr)
PE (1) PE20130155A1 (fr)
PH (1) PH12012501773A1 (fr)
PL (1) PL2558457T3 (fr)
RS (1) RS54708B1 (fr)
RU (1) RU2573560C2 (fr)
SG (1) SG183974A1 (fr)
SI (1) SI2558457T1 (fr)
TW (1) TWI445706B (fr)
UA (1) UA107491C2 (fr)
WO (1) WO2011128279A1 (fr)
ZA (1) ZA201207285B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010104818A1 (fr) * 2009-03-09 2010-09-16 Bristol-Myers Squibb Company Analogues d'azapyridone utiles comme antagonistes du récepteur 1 de l'hormone concentrant la mélanine
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
PL2702051T3 (pl) * 2011-04-26 2015-08-31 Hoffmann La Roche Pochodne etynylu jako pozytywne allosteryczne modulatory mglur5
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
EA026593B1 (ru) * 2012-07-17 2017-04-28 Ф. Хоффманн-Ля Рош Аг Арилэтиниловые производные
UA113223C2 (xx) * 2012-08-13 2016-12-26 Арилетинілпіримідини
JP6027251B2 (ja) * 2012-09-27 2016-11-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ アリールエチニル誘導体
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP3049409B1 (fr) * 2013-09-25 2017-05-03 F. Hoffmann-La Roche AG Dérivés d'éthynyle
TWI649310B (zh) * 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
MA39305A3 (fr) * 2014-02-25 2018-05-31 Hoffmann La Roche Dérivés d'éthynyle
CN107207481B (zh) * 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
LT3303316T (lt) * 2015-06-03 2020-05-11 F. Hoffmann-La Roche Ag Etinilo dariniai
ES2733468T3 (es) * 2015-07-15 2019-11-29 Hoffmann La Roche Derivados de etinilo como moduladores de los receptores metabotrópicos de glutamato
AR105556A1 (es) * 2015-08-03 2017-10-18 Hoffmann La Roche Derivados de etinilo
CN106632243B (zh) * 2015-10-28 2019-03-15 华领医药技术（上海）有限公司 吡咯烷衍生物
WO2018015235A1 (fr) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Dérivés d'éthynyle
CN108947883A (zh) * 2017-05-25 2018-12-07 北京万全德众医药生物技术有限公司 布瓦西坦的制备
JP7191045B2 (ja) * 2017-06-02 2022-12-16 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 化合物
WO2018220149A1 (fr) 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Composés
SG11202011818YA (en) 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
MA53220A (fr) * 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
ES2986417T3 (es) 2018-08-13 2024-11-11 Hoffmann La Roche Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
WO2020048826A1 (fr) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft Composés de la 1-oxa-3,9-diazaspiro[5.5]undécan-2-one substituée en position 5
ES2955037T3 (es) 2018-11-22 2023-11-28 Hoffmann La Roche Nuevos compuestos heterocíclicos
CN113993591A (zh) 2019-06-21 2022-01-28 豪夫迈·罗氏有限公司 新egfr抑制剂
CN114008049B (zh) 2019-06-21 2024-07-05 豪夫迈·罗氏有限公司 用于癌症治疗的egfr抑制剂
EP4028403B1 (fr) 2019-09-12 2023-11-22 F. Hoffmann-La Roche AG Composés de 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one comme inhibiteurs de magl
CN114018880B (zh) * 2021-10-22 2024-02-27 杭州食疗晶元生物科技有限公司 基于内源活性中间体对纯净水和天然矿泉水的鉴别方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI90869C (fi) * 1986-11-14 1994-04-11 Tanabe Seiyaku Co Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
GB9510744D0 (en) 1995-05-26 1995-07-19 Zeneca Ltd Chemical process
DE19546462A1 (de) * 1995-12-13 1997-06-19 Bayer Ag Diarylacetylenketone
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
EP1214303A1 (fr) 1999-08-31 2002-06-19 Merck & Co., Inc. Composes heterocycliques et procedes d'utilisation de ceux-ci
ES2252063T3 (es) * 1999-09-28 2006-05-16 Eisai Co., Ltd. Compuesto de quinuclidina y medicamento que comprende el compuesto como principio activo.
US7112593B2 (en) * 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
CL2004000847A1 (es) * 2003-04-23 2005-03-11 Schering Corp Compuestos derivados de 2-alquinil o 2-alquenil-5amino-pirazolo-[4,3-e]-1,2,4-triazolo[1,5-]pirimidina; composicion farmaceutica, y uso en el tratamiento de enfermedades del sistema nervioso central o un accidente cerebrovascular tal como depresion,
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7915424B2 (en) * 2004-03-22 2011-03-29 Eli Lilly And Company Pyridyl derivatives and their use as mGlu5 antagonists
JPWO2005108370A1 (ja) * 2004-04-16 2008-03-21 味の素株式会社 ベンゼン化合物
US7879882B2 (en) * 2004-10-07 2011-02-01 Merck Sharp & Dohme Corp. Thiazolyl mglur5 antagonists and methods for their use
WO2006048771A1 (fr) 2004-11-04 2006-05-11 Addex Pharmaceuticals Sa Nouveaux derives de tetrazole utilises comme modulateurs allosteriques positifs des recepteurs de glutamate metabotropiques
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
SG185285A1 (en) * 2007-06-03 2012-11-29 Univ Vanderbilt Benzamide mglur5 positive allosteric modulators and methods of making and using same
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
WO2010063487A1 (fr) * 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament
CN101544892B (zh) * 2009-05-07 2012-10-03 石家庄诚志永华显示材料有限公司 一种合成二芳基乙炔类单体液晶的方法
TW201116532A (en) * 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
US8389536B2 (en) * 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
UA110862C2 (uk) * 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5

Also Published As

Publication number Publication date
CA2786216A1 (fr) 2011-10-20
ES2565761T3 (es) 2016-04-06
BR112012026004A2 (pt) 2016-06-28
CY1117441T1 (el) 2017-04-26
IL220982A0 (en) 2012-09-24
US8420661B2 (en) 2013-04-16
MX2012011841A (es) 2012-11-09
DK2558457T3 (en) 2016-03-29
KR20130018294A (ko) 2013-02-20
RU2012145237A (ru) 2014-05-20
TW201136924A (en) 2011-11-01
JP2013523854A (ja) 2013-06-17
KR101431367B1 (ko) 2014-08-20
US8618296B2 (en) 2013-12-31
EP2558457A1 (fr) 2013-02-20
IL220982A (en) 2015-09-24
US20130178456A1 (en) 2013-07-11
HRP20160617T1 (hr) 2016-07-01
PH12012501773A1 (en) 2012-11-12
ECSP12012212A (es) 2012-10-30
SG183974A1 (en) 2012-10-30
AU2011240131A1 (en) 2012-07-19
US9315498B2 (en) 2016-04-19
RU2573560C2 (ru) 2016-01-20
EP2558457B1 (fr) 2016-03-09
UA107491C2 (uk) 2015-01-12
US20140155602A1 (en) 2014-06-05
WO2011128279A1 (fr) 2011-10-20
SI2558457T1 (sl) 2016-05-31
CR20120480A (es) 2012-10-30
HK1179607A1 (en) 2013-10-04
CL2012002771A1 (es) 2013-04-12
CA2786216C (fr) 2017-05-30
AR080878A1 (es) 2012-05-16
CN102947289A (zh) 2013-02-27
TWI445706B (zh) 2014-07-21
MY160490A (en) 2017-03-15
HUE027105T2 (en) 2016-08-29
US8513273B2 (en) 2013-08-20
PL2558457T3 (pl) 2016-09-30
AU2011240131B2 (en) 2015-01-22
CN102947289B (zh) 2014-06-11
US20130274464A1 (en) 2013-10-17
ZA201207285B (en) 2013-06-26
US20110251169A1 (en) 2011-10-13
PE20130155A1 (es) 2013-02-21
NZ601024A (en) 2014-08-29
JP5559418B2 (ja) 2014-07-23
RS54708B1 (sr) 2016-08-31

Similar Documents

Publication Publication Date Title
MA34078B1 (fr) Derives d'arylethynyle
MA34644B1 (fr) Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA38647B1 (fr) Dérivés 11-hydroxyle d'acides biliaires et leurs conjugués d'acides aminés en tant que modulateurs du récepteur de farnésoïde x
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
MA32882B1 (fr) Nouveaux pyrazole-4-n-alkoxycarboxamides en tant que microbiocides
ATE542813T1 (de) 6-substituierte 2- heterocyclylaminopyrazinverbindungen als chk-1- inhibitoren
UA114611C2 (uk) Пестицидні композиції і способи, що їх стосуються
SV2008002986A (es) Moduladores de indol sulfonamida de receptores de progesterona ref. x-17207
CR20130369A (es) Novedosos derivados heterocíclicos
MA35434B1 (fr) Amino-quinazolines en tant qu'inhibiteurs de kinase
MX2009003316A (es) Derivados de pirazina-2-carboxamida como moduladores receptores de cb2.
EA200901098A1 (ru) Производные тиазола в качестве модуляторов сопряженных с g-белком рецепторов
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
MA38403A1 (fr) Nouveaux dérivés de pyrazole modulateurs specifiques de cb2
SV2011003800A (es) Derivados de piridino-piridinonas, su preparacion y su aplicacion en terapeutica
MA38112A1 (fr) Dérivés d'imidazopyridazine en tant que modulateurs d'un récepteur gabaa
EA201000654A1 (ru) Производные тетразолов в качестве модуляторов метаботропных глутаматных рецепторов (mglur)
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
GT200900309A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica
EA201170997A1 (ru) Производные индола в качестве противораковых агентов
MX372721B (es) Ánalogos halogenados de agentes antifi-broticos.
EA200900090A1 (ru) Бензиламины, способ их получения и их применение в качестве противовоспалительных средств